Drugs / Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)
last change Jan 2025 re-read 2 minutes ago

Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)

Vaccine

Developed for
COVID-19
Investigated by
WestVac Biopharma (Guangzhou) Co., Ltd. · WestVac Biopharma Co., Ltd.

Trials 1 · a red edge is where a trial was stopped

202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT06175494 Dec 2023 → Jul 2024 COVID-19 WestVac Biopharma Co., Ltd. Unknown No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell) ClinicalTrials.gov intervention name — accepted as the source's own label NCT06175494
Modality Vaccine “Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)” NCT06175494